Atopic Dermatitis study: Tilrekimig vs Dupilumab
Official title A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
ClinicalTrials.gov ID: NCT07783425
What this study is testing
What is Tilrekimig?
Tilrekimig is an investigational medicine being studied as a potential treatment for moderate to severe atopic dermatitis (eczema).
Also referred to as PF-07275315.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study will see how well tilrekimig works, how safe it is, and how it changes the body in people with moderate‑to‑severe eczema.
- Who it's for
- Participants must be 12 years or older, have had eczema for at least a year, and not be responding well to skin‑applied medicines.
- What's involved
- You will receive either tilrekimig, another drug called dupilumab, or a placebo for 24 weeks, then a maintenance period. Visits and tests will be scheduled throughout the 52‑week study.
- Time commitment
- The study lasts 52 weeks, with visits during the first 24 weeks, a maintenance period, and a final safety follow‑up of 12 weeks after the last dose.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 and older
You may be able to join if
- Key You are [12] years of age or older
- You have had moderate-to-severe eczema for at least 1 year
- Topical medicines for eczema have not worked well for you Key
You likely can't join if
- Clinically Significant Autoimmune Disease
- Significant Infection History or Active Infection
- Known or Suspected Immunodeficiency/Immunosuppression
- Significant psychiatric illness or suicidality
- Clinically significant hepatic, renal, or hematologic abnormalities
The study team makes the final eligibility decision.
Where it is enrolling
- Birmingham, Alabama, United States
- Phoenix, Arizona, United States
- Bryant, Arkansas, United States
- Bakersfield, California, United States
- Huntington Beach, California, United States
- Laguna Niguel, California, United States
- Los Angeles, California, United States
- Northridge, California, United States
- Hialeah, Florida, United States
- Miami, Florida, United States
- Miami Lakes, Florida, United States
- Orlando, Florida, United States
- Macon, Georgia, United States
- Marietta, Georgia, United States
- Indianapolis, Indiana, United States
- Hunt Valley, Maryland, United States
- Ypsilanti, Michigan, United States
- Tulsa, Oklahoma, United States
- Memphis, Tennessee, United States
- Arlington, Texas, United States
+ 10 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 12 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Birmingham, Alabama, United States; Phoenix, Arizona, United States; Bryant, Arkansas, United States; Bakersfield, California, United States; Huntington Beach, California, United States; Laguna Niguel, California, United States and 24 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.